**Additional file 1 - Supplementary Table 1.**

Subanalysis of the features at baseline and follow-up of the groups receiving apremilast (APR) in monotherapy vs in combination with synthetic/biological drugs.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Combined**  **group**  **(N=20)** | **Monotherapy group**  **(N=31)** | **p** | |
| **Age, mean (SD) years** | 46.1 (12.6) | 43.8 (13.8) | | 0.65 |
| **Sex, men/women, n/n** | 7/13 | 9/22 | | 0.68 |
| **Months with Behçet disease before APR, mean (SD)** | 86.1 (82.6) | 81.1 (72.9) | | 0.52 |
| **Treatment before APR onset, (%)**  Oral glucocorticoids  Colchicine  NSAIDs  Methotrexate  Azathioprine  Adalimumab  Infliximab  Tocilizumab  Other treatments | 100  100  53  55  45  30  30  20  65 | 90  97  40  52  48  20  13  3.2  42 | | 0.15  0.42  0.38  0.81  0.81  0.41  0.13  **0.049**  0.27 |
| **Main clinical symptoms for starting APR, n (%)**  Oral ulcers  Genital ulcers  Oral and genital ulcers | 6 (30)  1 (5)  13 (65) | 13 (42)  1 (3)  17 (55) | | 0.67 |
| **Prednisone dose at APR onset, median [IQR], mg/d** | 10 [10-20] | 10 [5-20] | | 0.87 |
| **Concomitant treatment**  Oral glucocorticoids, n (%)  Colchicine, n (%)  NSAIDs, n (%)  Azathioprine, n  Methotrexate, n  Hydroxychloroquine, n  Sulfasalazine, n  Dapsone, n  Tocilizumab, n  Infliximab, n  Adalimumab, n | 13 (65)  11 (55)  5 (25)  7  5  4  1  1  2  1  1 | 15 (48)  14 (45)  10 (32)  0  0  0  0  0  0  0  0 | | 0.16  0.38  0.57 |
| **Follow-up on APR therapy, mean (SD), months** | 9.3 (7.8) | 7.8 (6.3) | | 0.31 |
| **Side effects, (%)**  Diarrhea  Dyspepsia  Headache  Nausea  Abdominal pain  Others | 21  21  26.3  10.5  10.5  0 | 23  20  13.3  33.3  6.7  19.4 | | 0.85  0.92  0.25  0.07  0.63  0.62 |

Results are expressed as mean ± standard deviation (SD), median [interquartile range: IQR] or as number (percentage: %), depending on the variable analyzed.